Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;55(3):553-561.
doi: 10.1038/s41409-019-0703-1. Epub 2019 Sep 26.

EASIX and mortality after allogeneic stem cell transplantation

Affiliations

EASIX and mortality after allogeneic stem cell transplantation

Thomas Luft et al. Bone Marrow Transplant. 2020 Mar.

Abstract

Allogeneic stem cell transplantation (alloSCT) is an effective immunotherapy in patients with hematological malignancies. Endothelial dysfunction was linked to major complications after alloSCT. We asked the question if the "Endothelial Activation and Stress Index" (EASIX; [(creatinine × LDH) ÷ thrombocytes]) can predict mortality after alloSCT. We performed a retrospective cohort analysis in five alloSCT centers in the USA and Germany. EASIX was assessed prior to conditioning (EASIX-pre) and correlated with mortality in 755 patients of a training cohort in multivariable models. The predictive model established in the training cohort was validated in 1267 adult allo-recipients. Increasing EASIX-pre predicted lower overall survival (OS) after alloSCT, and successful model validation was achieved for the validation cohort. We found that EASIX-pre predicts OS irrespective of established scores. Moreover, EASIX-pre was also a significant prognostic factor for transplant-associated microangiopathy. Finally, EASIX-pre correlated with biomarkers of endothelial homeostasis such as CXCL8, interleukin-18, and insulin-like-growth-factor-1 serum levels. This study establishes EASIX-pre based on a standard laboratory biomarker panel as a predictor of individual risk of mortality after alloSCT independently from established clinical criteria.

PubMed Disclaimer

Conflict of interest statement

Competing interest statement

The authors declare no competing interest.

Figures

Figure 1.
Figure 1.. Visualization of the univariable outcome analysis according to EASIX-pre quartiles A) training cohort, n=755, B) validation cohort (adult cohorts II-IV, n=1267).
Overall survival (OS), non-relapse mortality (NRM) and time to relapse (TTR) are shown according to the EASIX-pre quartiles raised in the respective cohorts. The high quartiles 4 (blue) and 3 (green) associate with lower OS and higher NRM in the training cohort and with lower OS, higher NRM and higher TTR in the validation cohort.
Figure 2.
Figure 2.. Model validation of EASIX as predictor of overall mortality
(A) Univariable model: The prediction error curve for EASIX-pre (red curve) developed in the Heidelberg training cohort of adult alloSCT recipients was computed for 36 months after alloSCT and compared with the reference (marginal Kaplan-Meier estimate, black curve). (B) Multivariable model: Confounders were adjusted to the validation cohort. The prediction error of EASIX-pre (green curve) developed in the multivariable Heidelberg training cohort was computed for 36 months and compared to the prediction error of the multivariable model without EASIX-pre (blue curve). A lower prediction error curve in the model including EASIX (red curve below black curve / green curve below blue curve) supports the usefulness of EASIX for predicting prognosis. C) Time-dependent concordance indices for overall survival. Color coding as in A and B: Highest concordance indices are found in the models including EASIX-pre (red: univariable, green: multivariable model with confounders adjusted to validation cohort and EASIX-pre, blue: multivariable model with confounders adjusted to validation cohort and without EASIX-pre). A concordance index of 0·5 (dotted line) implies random concordance. A concordance index above 0·6 is regarded as acceptable.

References

    1. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25(27): 4246–54. - PubMed
    1. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352(9134): 1087–92. - PubMed
    1. Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 115(20): 4715–26. - PubMed
    1. Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 2012; 120(4): 905–13. - PMC - PubMed
    1. Elsawy M, Sorror ML. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. Bone marrow transplantation 2016; 51(10): 1283–1300. - PubMed

Publication types